Profile cover photo
Profile photo
Synthetic Biologics, Inc.
36 followers -
A late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients
A late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients

36 followers
About
Synthetic Biologics, Inc.'s posts

Post has attachment
In a presentation at the 2017 BIO CEO & Investor Conference, President and CEO, Jeff Riley will provide an update on our two-lead microbiome-focused clinical programs designed to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C) and for the prevention of C. difficile infection & emergence of antimicrobial resistance. Register for the live webcast scheduled on 2/13/2017 at 4:00pm ET here: http://bit.ly/SYNBIO17 #microbiome #BIOCEO17

Post has attachment
Synthetic Biologics, Inc. announced today the award of a government contract from the Centers for Disease Control and Prevention (CDC) for research related to microbiome assessment and intervention to address antibiotic resistance. The contract, awarded through the CDC’s Broad Agency Announcement (BAA) 2016-N-17812, will support CDC’s efforts to assess how selective pressure from intravenous (IV) antibiotics may lead to the emergence of antibiotic resistance in the gut microbiome as well as SYN-004’s (ribaxamase) ability to prevent the emergence of antibiotic resistance in the gut microbiome. #antibioticresistance #microbiome bit.ly/CDCribax

Synthetic Biologics, Inc. announced today the completion of enrollment for its Phase 2b randomized, placebo-controlled, proof-of-concept clinical trial for SYN-004 (ribaxamase) designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of CDI, AAD and the emergence of antibiotic-resistant organisms. Top-line results are expected during the first quarter of 2017.  bit.ly/ribaxPH2bEE

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported its second quarter 2016 operational highlights and financial results. http://bit.ly/2aJjZ2 The Company will hold a conference call and webcast today, August 3, 2016 at 4:30pm EDT. Register here: http://bit.ly/SYN2Q16.

Post has attachment
Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced today the completion of its End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). The Agency provided its recommendation and guidance for the design of a Phase 2b/3 adaptive trial for SYN-010, intended to treat an underlying cause of IBS-C. The clinical trial is expected to commence during the first quarter of 2017. http://bit.ly/EOP2SYN010 #IBS-C #microbiome

Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its operational highlights and financial results for the three and six months ending June 30, 2016, on Wednesday, August 3, 2016, and to host a conference call the same day at 4:30 p.m. EDT. Register for the webcast here: http://bit.ly/SYN2Q16.

Post has attachment
Synthetic Biologics’ President and CEO, Jeff Riley, will present at the 2nd Annual Cantor Fitzgerald Healthcare Conference tomorrow, Wednesday, July 13th at 3:00pm EST. Register to listen to the live webcast: http://bit.ly/SYNCanFtz #Microbiome #SyntheticBiologics

Post has attachment
Synthetic Biologics announced today that the European Patent Office has granted European Patent No. 2576776, which provides composition of matter coverage for ribaxamase and represents the company’s first issued patent directly pertaining to ribaxamase in Europe. “The successful granting of this composition of matter patent in Europe further strengthens Synthetic Biologics’ role as a leader in the development of microbiome-focused programs,” said Jeffrey Riley, President and Chief Executive Officer. http://bit.ly/EU0716

Post has attachment
Synthetic Biologics’ President and CEO, Jeff Riley, will present at the 2nd Annual Cantor Fitzgerald Healthcare Conference on Wednesday, July 13th at 3:00pm EST. Register to listen to the live webcast: http://bit.ly/SYNCanFtz #Microbiome #SyntheticBiologics

Post has attachment
Synthetic Biologics’ SYN-004 – a first-in-class Phase II drug candidate that’s designed for the prevention of C. diff infection, antibiotic-associated diarrhea and the emergence of antibiotic-resistant organisms – has just received its generic name: Ribaxamase. A presentation is scheduled at this year’s ANAEROBE 2016. http://bit.ly/ribaxamase #Microbiome #Cdiff #AntibioticResistance
Wait while more posts are being loaded